Publishing research using ab62339? Please let us know so that we can cite the reference in this datasheet.

ab62339 has been referenced in 7 publications.

  • Booth L  et al. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8:1449-1468 (2017). ICC/IF . PubMed: 27903966
  • Booth L  et al. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget 8:16367-16386 (2017). PubMed: 28146421
  • Booth L  et al. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget 8:13464-13475 (2017). PubMed: 28088782
  • Booth L  et al. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 7:12975-96 (2016). PubMed: 26887051
  • Tavallai M  et al. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. Front Oncol 6:142 (2016). WB . PubMed: 27379204
  • Booth L  et al. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NF?B compensatory survival signaling. Oncotarget 7:23608-32 (2016). PubMed: 27015562
  • Booth L  et al. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. Oncotarget 7:40398-40417 (2016). PubMed: 27259258

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up